期刊文献+

骨肉瘤患者化疗后肿瘤坏死率与预后的相关性研究 被引量:5

Research on tumor necrosis rate in evaluating preoperative chemotherapy of osteosarcoma
下载PDF
导出
摘要 目的探讨骨肉瘤术前化疗后的肿瘤坏死率与预后的关系。方法选取2000年3月至2004年3月初诊经活检病理组织学诊断为骨肉瘤且经影像学检查排除远处转移的40例患者,术前给予大剂量甲氨蝶呤、阿霉素、顺铂和异环磷酰胺化疗1周期。根据对手术切除肿瘤标本的肿瘤坏死率测定将患者分为两组(肿瘤坏死率≥90%和<90%),分别随访两组患者的术后肺转移率和5年生存率并进行比较。结果 40例骨肉瘤患者中肿瘤坏死率≥90%组为23例,<90%组为17例,两组的术后肺转移率分别为21.7%和70.6%(χ2=11.831,P=0.001),5年生存率分别为78.3%和23.5%(χ2=9.545,P=0.002)。结论肿瘤坏死率测定是评价骨肉瘤术前化疗反应最直接可靠的方法,获肿瘤坏死率≥90%患者的远期转移率和生存时间优于肿瘤坏死率<90%患者。 Objective To discuss the relationship between tumor necrosis rate of preoperative chemotherapy and prognosis. Methods Forty osteosarcoma patients from March 2000 to March 2004 confirmed by pathology and excluded metastasis by imaging were enrolled in this study,who were given one cycle chemotherapy of large dose of methotrexate,adriacin,cisplatin and ifosfamide.These patients were divided into two groups according to tumor necrosis rate(≥90% and90%),and the postoperative lung metastasis rate and 5-year survival rate were compared. Results The patients in tumor necrosis rate≥90% and90% group were 23 cases and 17 cases.The 5-year survival rates in tumor necrosis rate≥90% and90% group were 78.3% and 23.5% and postoperative lung metastasis rate were 21.7% and 70.6% respectively,with statistical significances between the two groups(P〈0.05). Conclusion Tumor necrosis rate is a direct and reliable method for evaluation of preoperative chemotherapy on osteosarcoma.Patients with tumor necrosis rate≥90% have lower metastasis and longer survival than whose tumor necrosis rate90%.
出处 《临床肿瘤学杂志》 CAS 2011年第11期1001-1005,共5页 Chinese Clinical Oncology
关键词 骨肉瘤 新辅助化疗 肿瘤坏死率 预后 Osteosarcoma Neo-adjuvant chemotherapy Tumor necrosis rate Prognosis
  • 相关文献

参考文献5

二级参考文献44

  • 1李建民,杨强,杨志平,丰荣杰,迟增德,李昕.骨肉瘤髓腔内侵袭范围MRI测量与确定合理截骨平面的相关研究[J].中国矫形外科杂志,2005,13(23):1792-1794. 被引量:40
  • 2陈英鑫,李苏建,卢光明.肾CT和MR灌注成像应用进展[J].医学研究生学报,2007,20(5):535-539. 被引量:15
  • 3Clark J C, Dass C R, Choong P F. a review of clinical and molecular prognostic factors in osteosarcoma[J]. J Cancer Res Clin Oneol,2008,134(3):281- 297.
  • 4Miles K A. Measurement of tissue perfusion by dynamic computed tomography[J].Br J Radiol,1991,64(761):409-412.
  • 5Rumboldt Z, Al-Okaili R, Deveikis J P. Perfusion CT for Head and Neck Tumors: Pilot Study[J]. Am J Neuroradiol, 2005, 26(5) : 1178-1185.
  • 6Bisdas S, Baghi M, Wagenblast J, et al. Differentiation of benign and malignant parotid tumors using deconvolution-based perfu- sion CT imaging: Feasibility of the method and initial results[J].Eur J Radiol,2007,64(2):258 -265.
  • 7Hayano K, Okazumi S, Shuto K, et al. Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: Initial clinical results[J]. Oncol Rep,2007,18(4) :901-908.
  • 8Makari Y, Yasuda T, Doki Y, et al. eorrelation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers[J]. J Surg Oneol,2007, 96(3):220- 229.
  • 9Jain R, Ellika S K, Scarpace L, et al. Quantitative estimation of permeability surface area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade [J]. Am J Neuroradiol,2008,29(4) :694-700.
  • 10Sahani D V, Holalkere N S, Mueller P R, et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue initial experience[J].Radiology, 2007,243(3) : 736-743.

共引文献49

同被引文献38

  • 1夏贤良,杨迪生,范顺武,陈其昕.骨肉瘤的治疗──117例回顾[J].中华骨科杂志,1994,14(2):79-82. 被引量:14
  • 2牛晓辉,蔡槱伯,张清,郝林,丁易.ⅡB期肢体骨肉瘤189例综合治疗临床分析[J].中华外科杂志,2005,43(24):1576-1579. 被引量:41
  • 3Smith BR,Stabile BE. Extreme aggressiveness and lethali-ty of gastric adenocarcinoma in the very young[J]. ArchSurg,2009,144(2):506-510.
  • 4Marina N.Gebhardt M,Teot L, et al. Biology and thera-peutie advances for pediatric osteosarcoma [ J]. Oncolo-gist,2004,9(4) :422~441.
  • 5Bacci G,Longhi A,Fagioli F,et al. Adjuvant and neoadju-vant chemotherapy for osteosarcoma of the extremities:27year experience at Rizzoli Instute,Italy匸J], Eur J Career,2005,41(18).2836-2845.
  • 6Bramer JA* ven-Linge JH,Grimer RJ,et al. Prognosticfactors in localized extremity osteosarcoma: a systematicreview[J], Eur J Surg Oncol,2009,35(10) : 1030-1036.
  • 7Pakos EE,Nearchou AD,Grimer RJ,et al. Prognostic fac-tors and outcomes for osteosarcoma: an international col-laboration[J]. Eur J Cancer,2009,45(13) :2367-2375.
  • 8Kim MS,Lee SY,Lee TR,et al. Prognostic nomogram forpredicting the 5-year probability of developing metastasisafter neo-adjuvant chemotherapy and definitive surgeryfor AJCC stage U extremity osteosarcoma [J]. Ann On-col,2009,20(5) :955-960.
  • 9Aksnes LH,Bauer HC, Jebsen NL, et al. Limb-sparingsurgery preserves more function than amputation:a Scan-dinavian sarcoma group study of 118 patients[J]. J BoneJoint Surg Br,2008,90(6) :786-794.
  • 10Coorin AM, Schwartzentruber DJ, Devidas M,et al. Pres-urgical chemotherapy compared with immediate surgeryand adjuvant chemotherapy for nonmetastatic osteosarco-ma: Pediatric Oncol-ogy Group Study[J], J Clin Oncol.2003,21(8):1574-1580.

引证文献5

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部